Merck posted robust top-line gains driven by enduring demand for blockbuster oncology drug Keytruda and rapid market adoption of newly launched Winrevair.

Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.

AstraZeneca is advancing a portfolio of targeted cancer therapies to protect oncology margins and achieve its ambitious 2030 revenue targets.

Swiss pharmaceutical powerhouse Roche is ramping up its oncology pipeline, targeting critical gaps in lung cancer care across key emerging markets.